MyFinsight
Home
About
Contact
Back
Income Statement
CUMBERLAND PHARMACEUTICALS INC (CPIX)
source: myfinsight.com
Download
Download image
Net income (loss)
attributable to common...
-$740,740
(31.77%↑ Y/Y)
Net loss (income) at
subsidiary attributable to...
$5,533
(132.50%↑ Y/Y)
Net income (loss)
-$735,207
(33.32%↑ Y/Y)
Income (loss) before
income taxes
-$729,536
(33.14%↑ Y/Y)
Income tax expense
$5,671
(-50.44%↓ Y/Y)
Interest income
$127,489
(106.16%↑ Y/Y)
Revenues, including
adjustments-Product Redi Trex
$3,244
Product Acetadote
$193,546
Product Caldolor
$1,588,293
Product Kristalose
$2,754,299
Product Other
$492,390
Product Sancuso
$3,119,110
Product Vibativ
$2,701,854
Interest expense
$109,547
(-13.30%↓ Y/Y)
Operating income (loss)
-$747,478
(27.20%↑ Y/Y)
Net revenues
$10,837,363
(10.04%↑ Y/Y)
Revenues, including
adjustments-Product Omeclamox Pak
-$14,621
Revenues, including
adjustments-Product Vaprisol
-$752
Total costs and
expenses
$11,584,841
(6.52%↑ Y/Y)
Amortization
$1,006,484
(-8.49%↓ Y/Y)
Cost of products sold
$2,011,389
(17.56%↑ Y/Y)
General and
administrative
$2,874,922
(4.27%↑ Y/Y)
Research and development
$1,468,399
(38.63%↑ Y/Y)
Selling and marketing
$4,223,647
(-0.58%↓ Y/Y)
Back